BR112012009401A2 - vacinas que compreendem transgenes sensíveis ao calor - Google Patents

vacinas que compreendem transgenes sensíveis ao calor

Info

Publication number
BR112012009401A2
BR112012009401A2 BR112012009401A BR112012009401A BR112012009401A2 BR 112012009401 A2 BR112012009401 A2 BR 112012009401A2 BR 112012009401 A BR112012009401 A BR 112012009401A BR 112012009401 A BR112012009401 A BR 112012009401A BR 112012009401 A2 BR112012009401 A2 BR 112012009401A2
Authority
BR
Brazil
Prior art keywords
nucleic acid
acid molecules
transgenes
vaccines
heat sensitive
Prior art date
Application number
BR112012009401A
Other languages
English (en)
Inventor
E Nano Francis
Original Assignee
Uvic Ind Partnerships Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uvic Ind Partnerships Inc filed Critical Uvic Ind Partnerships Inc
Publication of BR112012009401A2 publication Critical patent/BR112012009401A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1014—Hydroxymethyl-, formyl-transferases (2.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Abstract

vacinas que compreendem transgenes sensíveis ao calor. a presente revelação fornece moléculas de ácido nucleico essencial sensíveis à temperatura de uma bacterística psicrofílica, proteínas codificadas pelas moléculas de ácido nucleico, bem como células recombinantes em que foram introduzidas tais moléculas de ácido nucleico. as cálulas recombinantes reveladas que contêm um ou mais moléculas de ácido nucleico essenciais de uma bactéria psicrofílica tornam-se assim sensíveis à temperatura e podem ser administradas a um mamífero para induzir uma respota imune no mamífero.
BR112012009401A 2009-10-07 2010-10-07 vacinas que compreendem transgenes sensíveis ao calor BR112012009401A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24938509P 2009-10-07 2009-10-07
US32263410P 2010-04-09 2010-04-09
PCT/CA2010/001561 WO2011041886A1 (en) 2009-10-07 2010-10-07 Vaccines comprising heat-sensitive transgenes

Publications (1)

Publication Number Publication Date
BR112012009401A2 true BR112012009401A2 (pt) 2017-02-21

Family

ID=43856334

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012009401A BR112012009401A2 (pt) 2009-10-07 2010-10-07 vacinas que compreendem transgenes sensíveis ao calor

Country Status (10)

Country Link
US (3) US8778683B2 (pt)
EP (1) EP2486133B1 (pt)
CN (1) CN102782138A (pt)
AU (1) AU2010305273B2 (pt)
BR (1) BR112012009401A2 (pt)
CA (1) CA2776922A1 (pt)
ES (1) ES2594485T3 (pt)
HR (1) HRP20161234T1 (pt)
HU (1) HUE029386T2 (pt)
WO (1) WO2011041886A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019012667A (es) * 2017-04-28 2020-01-21 Univ Kansas State Metodos de interrupcion de gen dirigido y composiciones inmunogenicas.
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5376369A (en) * 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
US5270202A (en) 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
DE69225710T3 (de) 1991-07-25 2004-10-14 Idec Pharmaceuticals Corp., San Diego Anregung von antworten zytotoxischer t-lymphozyten
US5709860A (en) 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
CA2281838A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
CA2301575C (en) 1997-05-20 2003-12-23 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
CA2323929C (en) 1998-04-03 2004-03-09 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
EP1245679A4 (en) * 1999-12-21 2005-03-16 Japan Science & Tech Agency IMPF STAMPS AGAINST INFECTIONS WITH PATHOGENIC BACTERIA
WO2005035750A2 (en) * 2003-10-13 2005-04-21 Gesellschaft Für Biotechnologische Forschung Transgenic organisms with lower growth temperature
WO2007067729A2 (en) * 2005-12-09 2007-06-14 University Of Georgia Research Foundation, Inc. Microbial vaccine and vaccine vector
GB2444903A (en) * 2006-12-21 2008-06-25 Secr Defence Live Francisella vaccine, inactivated at gene FTT1564

Also Published As

Publication number Publication date
US20170136111A1 (en) 2017-05-18
US20130177589A1 (en) 2013-07-11
WO2011041886A1 (en) 2011-04-14
WO2011041886A8 (en) 2011-06-09
HUE029386T2 (en) 2017-02-28
EP2486133A4 (en) 2013-10-16
EP2486133A1 (en) 2012-08-15
EP2486133B1 (en) 2016-06-29
CN102782138A (zh) 2012-11-14
HRP20161234T1 (hr) 2016-12-02
CA2776922A1 (en) 2011-04-14
AU2010305273A1 (en) 2012-04-19
ES2594485T3 (es) 2016-12-20
AU2010305273B2 (en) 2016-09-29
US9580478B2 (en) 2017-02-28
US8778683B2 (en) 2014-07-15
US20120189661A1 (en) 2012-07-26

Similar Documents

Publication Publication Date Title
BR112012033699A2 (pt) polipeptídeo tendo atividade beta-glicosidase e seus usos
BR112012033404A2 (pt) polipetídeo tendo ou auxiliando a atividade de degradação de material de carboidratos e uso dos mesmos.
BR112015022971A2 (pt) métodos de fabricação para controlar o teor de lisina c-terminal, galactose e ácido siálico em proteínas recombinantes
MX2018001040A (es) Moleculas de acido nucleico artificiales.
BR112012033703A2 (pt) polipeptídeo tendo atividade beta-glicosidase e seus usos
BR112012018075A2 (pt) "sistema e método de formação e dimensionamento de goma de mascar e/ou de alteração da temperatura da goma de mascar".
BR112012013875B8 (pt) método in vitro para reprogramar células somáticas humanas ou de outros mamíferos para células tronco pluripotentes induzidas (células ips ou ipscs) e composição
BR112012028805A2 (pt) composições de endorribonuclease e métodos de uso das mesmas.
BR112016007727A2 (pt) célula hospedeira, métodos para produzir um glicoconjugado, uma célula hospedeira e uma proteína n-glicosilada, para tratar ou prevenir uma infecção em um indivíduo e para induzir uma resposta imune em um indivíduo, glicoconjugado, kit, e, plasmídeo isolado
BR112014018916A2 (pt) classe de genes de resistência a glifosato
BR112014001909A2 (pt) gene da toxina axmi270 e métodos para a sua utilização
BR112014022166A2 (pt) gene da delta-endotoxina axmi345 e métodos para a sua utilização
EA201400995A1 (ru) Способы повышения выносливости к тепловому стрессу и содержания аминокислот в растениях
BR112012033714A2 (pt) polipeptídeo com atividade de acetil xilano esterase e seus usos.
BR112016022055A2 (pt) elementos de ligação ao tnf alfa
BR112014017188A8 (pt) células hospedeiras com endossimbiontes artificiais
BR112014032636A2 (pt) Vacinas atenuadas de streptococcus suis e métodos de produção e usos das mesmas
BR112012028893A2 (pt) composições imunoestimuladoras e de vacina
BR112014022034A2 (pt) gene da toxina axmi335 de bacillus thuringiensis e métodos para a sua utilização
BR112016007641A2 (pt) método para controle de temperatura em um reator, e, reator
MX363187B (es) Métodos y composiciones para impedir la incorrecta incorporación de norleucina en proteínas.
EA201691011A1 (ru) Последовательность модифицированного эндолизина el188
BR112012033701A2 (pt) polipeptídeo tendo atividade de degradação de carbohidrato e seus usos
BR112016010159A2 (pt) usos de um conjunto de ácidos nucleicos e de um chip de microarranjo, chip de microarranjo, métodos para detecção de patógenos e/ou microrganismos benéficos em uma amostra orgânica e de tratamento de uma relva doente, e, kit
BR112012009401A2 (pt) vacinas que compreendem transgenes sensíveis ao calor

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2534 DE 30-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.